Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling

S. M. Kurian, A. N. Williams, T. Gelbart, D. Campbell, T. S. Mondala, S. R. Head, S. Horvath, L. Gaber, R. Thompson, T. Whisenant, W. Lin, P. Langfelder, E. H. Robison, R. L. Schaffer, J. S. Fisher, J. Friedewald, S. M. Flechner, L. K. Chan, A. C. Wiseman, H. ShidbanR. Mendez, R. Heilman, M. M. Abecassis, C. L. Marsh, D. R. Salomon

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

There are no minimally invasive diagnostic metrics for acute kidney transplant rejection (AR), especially in the setting of the common confounding diagnosis, acute dysfunction with no rejection (ADNR). Thus, though kidney transplant biopsies remain the gold standard, they are invasive, have substantial risks, sampling error issues and significant costs and are not suitable for serial monitoring. Global gene expression profiles of 148 peripheral blood samples from transplant patients with excellent function and normal histology (TX; n = 46), AR (n = 63) and ADNR (n = 39), from two independent cohorts were analyzed with DNA microarrays. We applied a new normalization tool, frozen robust multi-array analysis, particularly suitable for clinical diagnostics, multiple prediction tools to discover, refine and validate robust molecular classifiers and we tested a novel one-by-one analysis strategy to model the real clinical application of this test. Multiple three-way classifier tools identified 200 highest value probesets with sensitivity, specificity, positive predictive value, negative predictive value and area under the curve for the validation cohort ranging from 82% to 100%, 76% to 95%, 76% to 95%, 79% to 100%, 84% to 100% and 0.817 to 0.968, respectively. We conclude that peripheral blood gene expression profiling can be used as a minimally invasive tool to accurately reveal TX, AR and ADNR in the setting of acute kidney transplant dysfunction. This study of kidney transplantation describes a three-way classifier based on global gene expression profiling of peripheral blood and the blood signatures of patients with excellent functioning grafts that can be used in the setting of acute kidney transplant dysfunction to accurately distinguish between biopsy-proven acute rejection and acute dysfunction with no rejection.

Original languageEnglish (US)
Pages (from-to)1164-1172
Number of pages9
JournalAmerican Journal of Transplantation
Volume14
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Graft Rejection
Gene Expression Profiling
Genome
Transplants
Kidney
Biopsy
Selection Bias
Oligonucleotide Array Sequence Analysis
Transcriptome
Kidney Transplantation
Area Under Curve
Histology
Costs and Cost Analysis
Sensitivity and Specificity

Keywords

  • Acute dysfunction with no rejection
  • acute kidney rejection
  • gene expression profiling
  • microarrays
  • molecular classifiers

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Kurian, S. M., Williams, A. N., Gelbart, T., Campbell, D., Mondala, T. S., Head, S. R., ... Salomon, D. R. (2014). Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling. American Journal of Transplantation, 14(5), 1164-1172. https://doi.org/10.1111/ajt.12671

Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling. / Kurian, S. M.; Williams, A. N.; Gelbart, T.; Campbell, D.; Mondala, T. S.; Head, S. R.; Horvath, S.; Gaber, L.; Thompson, R.; Whisenant, T.; Lin, W.; Langfelder, P.; Robison, E. H.; Schaffer, R. L.; Fisher, J. S.; Friedewald, J.; Flechner, S. M.; Chan, L. K.; Wiseman, A. C.; Shidban, H.; Mendez, R.; Heilman, R.; Abecassis, M. M.; Marsh, C. L.; Salomon, D. R.

In: American Journal of Transplantation, Vol. 14, No. 5, 2014, p. 1164-1172.

Research output: Contribution to journalArticle

Kurian, SM, Williams, AN, Gelbart, T, Campbell, D, Mondala, TS, Head, SR, Horvath, S, Gaber, L, Thompson, R, Whisenant, T, Lin, W, Langfelder, P, Robison, EH, Schaffer, RL, Fisher, JS, Friedewald, J, Flechner, SM, Chan, LK, Wiseman, AC, Shidban, H, Mendez, R, Heilman, R, Abecassis, MM, Marsh, CL & Salomon, DR 2014, 'Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling', American Journal of Transplantation, vol. 14, no. 5, pp. 1164-1172. https://doi.org/10.1111/ajt.12671
Kurian, S. M. ; Williams, A. N. ; Gelbart, T. ; Campbell, D. ; Mondala, T. S. ; Head, S. R. ; Horvath, S. ; Gaber, L. ; Thompson, R. ; Whisenant, T. ; Lin, W. ; Langfelder, P. ; Robison, E. H. ; Schaffer, R. L. ; Fisher, J. S. ; Friedewald, J. ; Flechner, S. M. ; Chan, L. K. ; Wiseman, A. C. ; Shidban, H. ; Mendez, R. ; Heilman, R. ; Abecassis, M. M. ; Marsh, C. L. ; Salomon, D. R. / Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling. In: American Journal of Transplantation. 2014 ; Vol. 14, No. 5. pp. 1164-1172.
@article{9436a9a23f4646e8ab2839b424e71b15,
title = "Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling",
abstract = "There are no minimally invasive diagnostic metrics for acute kidney transplant rejection (AR), especially in the setting of the common confounding diagnosis, acute dysfunction with no rejection (ADNR). Thus, though kidney transplant biopsies remain the gold standard, they are invasive, have substantial risks, sampling error issues and significant costs and are not suitable for serial monitoring. Global gene expression profiles of 148 peripheral blood samples from transplant patients with excellent function and normal histology (TX; n = 46), AR (n = 63) and ADNR (n = 39), from two independent cohorts were analyzed with DNA microarrays. We applied a new normalization tool, frozen robust multi-array analysis, particularly suitable for clinical diagnostics, multiple prediction tools to discover, refine and validate robust molecular classifiers and we tested a novel one-by-one analysis strategy to model the real clinical application of this test. Multiple three-way classifier tools identified 200 highest value probesets with sensitivity, specificity, positive predictive value, negative predictive value and area under the curve for the validation cohort ranging from 82{\%} to 100{\%}, 76{\%} to 95{\%}, 76{\%} to 95{\%}, 79{\%} to 100{\%}, 84{\%} to 100{\%} and 0.817 to 0.968, respectively. We conclude that peripheral blood gene expression profiling can be used as a minimally invasive tool to accurately reveal TX, AR and ADNR in the setting of acute kidney transplant dysfunction. This study of kidney transplantation describes a three-way classifier based on global gene expression profiling of peripheral blood and the blood signatures of patients with excellent functioning grafts that can be used in the setting of acute kidney transplant dysfunction to accurately distinguish between biopsy-proven acute rejection and acute dysfunction with no rejection.",
keywords = "Acute dysfunction with no rejection, acute kidney rejection, gene expression profiling, microarrays, molecular classifiers",
author = "Kurian, {S. M.} and Williams, {A. N.} and T. Gelbart and D. Campbell and Mondala, {T. S.} and Head, {S. R.} and S. Horvath and L. Gaber and R. Thompson and T. Whisenant and W. Lin and P. Langfelder and Robison, {E. H.} and Schaffer, {R. L.} and Fisher, {J. S.} and J. Friedewald and Flechner, {S. M.} and Chan, {L. K.} and Wiseman, {A. C.} and H. Shidban and R. Mendez and R. Heilman and Abecassis, {M. M.} and Marsh, {C. L.} and Salomon, {D. R.}",
year = "2014",
doi = "10.1111/ajt.12671",
language = "English (US)",
volume = "14",
pages = "1164--1172",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling

AU - Kurian, S. M.

AU - Williams, A. N.

AU - Gelbart, T.

AU - Campbell, D.

AU - Mondala, T. S.

AU - Head, S. R.

AU - Horvath, S.

AU - Gaber, L.

AU - Thompson, R.

AU - Whisenant, T.

AU - Lin, W.

AU - Langfelder, P.

AU - Robison, E. H.

AU - Schaffer, R. L.

AU - Fisher, J. S.

AU - Friedewald, J.

AU - Flechner, S. M.

AU - Chan, L. K.

AU - Wiseman, A. C.

AU - Shidban, H.

AU - Mendez, R.

AU - Heilman, R.

AU - Abecassis, M. M.

AU - Marsh, C. L.

AU - Salomon, D. R.

PY - 2014

Y1 - 2014

N2 - There are no minimally invasive diagnostic metrics for acute kidney transplant rejection (AR), especially in the setting of the common confounding diagnosis, acute dysfunction with no rejection (ADNR). Thus, though kidney transplant biopsies remain the gold standard, they are invasive, have substantial risks, sampling error issues and significant costs and are not suitable for serial monitoring. Global gene expression profiles of 148 peripheral blood samples from transplant patients with excellent function and normal histology (TX; n = 46), AR (n = 63) and ADNR (n = 39), from two independent cohorts were analyzed with DNA microarrays. We applied a new normalization tool, frozen robust multi-array analysis, particularly suitable for clinical diagnostics, multiple prediction tools to discover, refine and validate robust molecular classifiers and we tested a novel one-by-one analysis strategy to model the real clinical application of this test. Multiple three-way classifier tools identified 200 highest value probesets with sensitivity, specificity, positive predictive value, negative predictive value and area under the curve for the validation cohort ranging from 82% to 100%, 76% to 95%, 76% to 95%, 79% to 100%, 84% to 100% and 0.817 to 0.968, respectively. We conclude that peripheral blood gene expression profiling can be used as a minimally invasive tool to accurately reveal TX, AR and ADNR in the setting of acute kidney transplant dysfunction. This study of kidney transplantation describes a three-way classifier based on global gene expression profiling of peripheral blood and the blood signatures of patients with excellent functioning grafts that can be used in the setting of acute kidney transplant dysfunction to accurately distinguish between biopsy-proven acute rejection and acute dysfunction with no rejection.

AB - There are no minimally invasive diagnostic metrics for acute kidney transplant rejection (AR), especially in the setting of the common confounding diagnosis, acute dysfunction with no rejection (ADNR). Thus, though kidney transplant biopsies remain the gold standard, they are invasive, have substantial risks, sampling error issues and significant costs and are not suitable for serial monitoring. Global gene expression profiles of 148 peripheral blood samples from transplant patients with excellent function and normal histology (TX; n = 46), AR (n = 63) and ADNR (n = 39), from two independent cohorts were analyzed with DNA microarrays. We applied a new normalization tool, frozen robust multi-array analysis, particularly suitable for clinical diagnostics, multiple prediction tools to discover, refine and validate robust molecular classifiers and we tested a novel one-by-one analysis strategy to model the real clinical application of this test. Multiple three-way classifier tools identified 200 highest value probesets with sensitivity, specificity, positive predictive value, negative predictive value and area under the curve for the validation cohort ranging from 82% to 100%, 76% to 95%, 76% to 95%, 79% to 100%, 84% to 100% and 0.817 to 0.968, respectively. We conclude that peripheral blood gene expression profiling can be used as a minimally invasive tool to accurately reveal TX, AR and ADNR in the setting of acute kidney transplant dysfunction. This study of kidney transplantation describes a three-way classifier based on global gene expression profiling of peripheral blood and the blood signatures of patients with excellent functioning grafts that can be used in the setting of acute kidney transplant dysfunction to accurately distinguish between biopsy-proven acute rejection and acute dysfunction with no rejection.

KW - Acute dysfunction with no rejection

KW - acute kidney rejection

KW - gene expression profiling

KW - microarrays

KW - molecular classifiers

UR - http://www.scopus.com/inward/record.url?scp=84899012442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899012442&partnerID=8YFLogxK

U2 - 10.1111/ajt.12671

DO - 10.1111/ajt.12671

M3 - Article

C2 - 24725967

AN - SCOPUS:84899012442

VL - 14

SP - 1164

EP - 1172

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 5

ER -